Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy

Expert Review of Vaccines

Volumn 14, Issue 9, 2015, Pages 1255-1275

  Zheng, Yuan Qiang ^a   Naguib, Youssef W ^b   Dong, Yixuan ^b   Shi, Yan Chun ^a   Bou, Shorgan ^c   Cui, Zhengrong ^a,b  

^a INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c INNER MONGOLIA UNIVERSITY   (China)

Author keywords

Bacillus Calmette Guerin; bacterial vector; bladder cancer; clinical applications; infectious disease; recombinant BCG; tumor; vaccine development

Indexed keywords

BCG VACCINE; CYTOKINE; IMMUNOMODULATING AGENT; RECOMBINANT VACCINE; BACTERIAL VACCINE; CANCER VACCINE; DRUG CARRIER; LIVE VACCINE; VIRUS VACCINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION CONTROL; INFECTION PREVENTION; MENINGITIS; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BACTERIAL INFECTIONS; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; MYCOBACTERIUM BOVIS; NEOPLASMS; PARASITIC DISEASES; PROCEDURES; TRENDS; VIRUS DISEASES;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; CANCER VACCINES; DRUG CARRIERS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM BOVIS; NEOPLASMS; PARASITIC DISEASES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUS DISEASES;

EID: 84939454595     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1068124     Document Type: Review

References (208)

1. Milstien J. Expanded programme on immunization. Module 5: Tuberculosis. Immunol Basis Immun Series 1993;93(15): 1-12
2. Ahn JJ, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory bladder cancer. Urol Clin North Am 2013;40(2): 219-32
3. Kremer L, Dupre L, Riveau G, et al. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun 1998;66(12): 5669-76
4. Kawahara M, Hashimoto A, Toida I, Honda M. Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol 2002;105(3): 326-31
5. Kawahara M, Matsuo K, Nakasone T, et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 2002;21(3-4):158-66
6. Mederle I, Le GR, Vaslin B, et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 2003;21(27-30):4153-66
7. Mederle I, Bourguin I, Ensergueix D, et al. Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun 2002; 70(1):303-14
8. Langermann S, Palaszynski S, Sadziene A, et al. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 1994;372(6506):552-5
9. Langermann S, Palaszynski SR, Burlein JE, et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J Exp Med 1994;180(6):2277-86
10. Matsuo K, Yasutomi Y. Mycobacterium bovis Bacille Calmette-Guerin as a Vaccine Vector for Global Infectious Disease Control. Tuberc Res Treat 2011;2011:574591
11. Chapman R, Stutz H, Jacobs W Jr, et al. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice. PLoS One 2013;8(8):e71601
12. Fujii J, Naito M, Yutsudo T, et al. Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. Clin Vaccine Immunol 2012;19(12):1932-7
13. Arama C, Ssefaw-Redda Y, Rodriguez A, et al. Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guerin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice. Vaccine 2012;30(27):4040-5
14. Arama C, Waseem S, Fernandez C, et al. A recombinant Bacille Calmette-Guerin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine 2012;30(37):5578-84
15. Yu DS, Lee CF, Hsieh DS, Chang SY. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 2004;63(3):596-601
16. Dhar N, Rao V, Tyagi AK. Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol 2004;193(1):19-25
17. Andrade PM, Chade DC, Borra RC, et al. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer. Urol Oncol 2010;28(5):520-5
18. Buddle BM, Parlane NA, Wedlock DN, Heiser A. Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans. Transbound Emerg Dis 2013; 60(Suppl 1):136-46
19. Calmette A, Guerin C, Ne'gre L, Boquet A. Premunition des nouveaux-nescontre la tuberculoseparllevaccin BCG, 1921-1926. Annales de l'Institut Pasteur (Paris) 1926;40:89-133
20. Brosch R, Gordon SV, Pym A, et al. Comparative genomics of the mycobacteria. Int J Med Microbiol 2000;290(2):143-52
21. Sante-Poku A, Yeboah-Manu D, Otchere ID, et al. Mycobacterium africanum is associated with patient ethnicity in Ghana 1. PLoS Negl Trop Dis 2015;9(1):e3370
22. Tientcheu LD, Sutherland JS, de Jong BC, et al. Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients 1. Eur J Immunol 2014;44(5):1387-98
23. Ueyama M, Chikamatsu K, Aono A, et al. Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan 1. Tuberculosis (Edinb) 2014;94(1):15-19
24. WHO. Global tuberculosis report 2013. World Health Organization 2013
25. Weiner J III, Kaufmann SH. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014;275(5):467-80
26. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393(6685):537-44
27. Cuello-Garcia CA, Perez-Gaxiola G, Jimenez GC. Treating BCG-induced disease in children. Cochrane Database Syst Rev 2013;1:CD008300
28. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children 1. Vaccine 2007; 25(1):14-18
29. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children 1. Clin Infect Dis 2006;42(4): 548-58
30. Hesseling AC, Cotton MF, Fordham von RC, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants 1. Int J Tuberc Lung Dis 2008;12(12):1376-9
31. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22(6): 1154-8
32. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007;104(13):5596-601
33. Rentsch CA, Birkhauser FD, Biot C, et al. Bacillus calmette-guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014;66(4):677-88
34. Hayashi D, Takii T, Fujiwara N, et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 2009;56(2):116-28
35. Rodriguez-Alvarez M, Mendoza-Hernandez G, Encarnacion S, et al. Phenotypic differences between BCG vaccines at the proteome level. Tuberculosis (Edinb) 2009;89(2):126-35
36. Hayashi D, Takii T, Mukai T, et al. Biochemical characteristics among Mycobacterium bovis BCG substrains. FEMS Microbiol Lett 2010;306(2):103-9
37. Castillo-Rodal AI, Castanon-Arreola M, Hernandez-Pando R, et al. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006;74(3):1718-24
38. Behr MA. BCG-different strains, different vaccines? Lancet Infect Dis 2002;2(2):86-92
39. Fine PE, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes: a discussion document. World Health Organization; Geneva: 1999
40. Gan C, Mostafid H, Khan MS, Lewis DJ. BCG immunotherapy for bladder cancer-the effects of substrain differences. Nat Rev Urol 2013;10(10):580-8
41. Oettinger T, Jorgensen M, Ladefoged A, et al. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 1999;79(4):243-50
42. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179(1):53-6
43. Jungblut PR, Schaible UE, Mollenkopf HJ, et al. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 1999;33(6):1103-17
44. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284(5419):1520-3
45. Behr MA, Schroeder BG, Brinkman JN, et al. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. J Bacteriol 2000;182(12):3394-9
46. Sengiku A, Ito M, Miyazaki Y, et al. A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 2013;190(1):50-4
47. Inamoto T, Ubai T, Nishida T, et al. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guerin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison. Urol Ann 2013;5(1):7-12
48. Yuan Y, Zhu Y, Crane DD, Barry CE III. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis 1. Mol Microbiol 1998;29(6): 1449-58
49. Davids V, Hanekom WA, Mansoor N, et al. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 2006;193(4):531-6
50. Cohn DL. Use of the bacille Calmette-Guerin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine 1. Am J Med Sci 1997; 313(6):372-6
51. Liu J, Tran V, Leung AS, et al. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy 1. Hum Vaccin 2009;5(2):70-8
52. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59(6):997-1008
53. Hsu JW, Yin PN, Wood R, et al. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guerin immunotherapy of bladder cancer. Oncotarget 2013(12):2397-406
54. van Lingen AV, Witjes JA. Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther 2013;13(10):1371-85
55. Askeland EJ, Newton MR, O'Donnell MA, Luo Y. Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol 2012;2012:181987
56. Gontero P, Bohle A, Malmstrom PU, et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010;57(3):410-29
57. Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009;1(2):281-8
58. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1): 90-5
59. Jarvinen R, Kaasinen E, Sankila A, Rintala E. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56(2): 260-5
60. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247-56
61. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3): 209-16
62. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180-3
63. deKernion JB, Golub SH, Gupta RK, et al. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer 1975;36(5):1662-7
64. Bloomberg SD, Brosman SA, Hausman MS, et al. The effects of BCG on the dog bladder. Invest Urol 1975;12(6):423-7
65. Kapoor R, Vijjan V, Singh P. Bacillus Calmette-Guerin in the management of superficial bladder cancer. Indian J Urol 2008;24(1):72-6
66. Luo Y, Henning J, O'Donnell MA. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol 2011;2011:728930
67. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163(4):1124-9
68. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86-90
69. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766-73
70. Inman BA, Abern MR. Maintenance bacillus Calmette-Guerin: why is there continued debate? Eur Urol 2013;64(4): 586-7
71. Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64(4):579-85
72. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediateand high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462-72
73. Lamm D. Superficial bladder cancer. Curr Treat Options in Oncol 2002;3(5):403-11
74. Farah NB, Ghanem R, Amr M. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC). BMC Urol 2014;14:11
75. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement 1. Biomed Pharmacother 2007;61(6):299-305
76. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990;85(1):62-7
77. Kuroda K, Brown EJ, Telle WB, et al. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993;91(1):69-76
78. Sapre N, Corcoran NM. Modulating the immune response to Bacillus Calmette-Guerin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer? BJU Int 2013;112(6):852-3
79. Kawai K, Miyazaki J, Joraku A, et al. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013; 104(1):22-7
80. de Boer EC, De Jong WH, Steerenberg PA, et al. Induction of urinary interleukin-1 (IL- 1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 1992;34(5):306-12
81. Zuiverloon TC, Nieuweboer AJ, Vekony H, et al. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012;61(1): 128-45
82. Miyazaki J, Kawai K, Oikawa T, et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling. BJU Int 2006;97(4):860-4
83. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353(9165):1689-94
84. Kitamura H, Tsukamoto T. Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) 2011;3(3):3055-72
85. Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150(3):1018-23
86. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosisinducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009;28(3-4):345-53
87. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16(1):21-6
88. Diehl GE, Yue HH, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21(6):877-89
89. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosisinducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004;64(10):3386-90
90. Simons MP, Moore JM, Kemp TJ, Griffith TS. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun 2007;75(3): 1265-71
91. Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int 2013; 112(3):288-97
92. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995; 99(3):369-75
93. Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 2012;4(137): 137ra72
94. Schwarzer K, Foerster M, Steiner T, et al. BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int 2010;10:21
95. Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007;52(5):1398-406
96. Zhang D, Sun P, Li P, et al. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guerin in the treatment of bladder cancer. Biomaterials 2013;34(38): 10258-66
97. Lotan Y. The challenge of bacillus Calmette-Guerin failure in nonmuscle invasive bladder cancer-what is the next step in management? J Urol 2013;190(3): 832-3
98. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175(6):2004-10
99. Chade DC, Borra RC, Nascimento IP, et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008;27:78
100. Begnini KR, Rizzi C, Campos VF, et al. Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro. Appl Microbiol Biotechnol 2013;97(4):1543-52
101. Sternberg IA, Dalbagni G, Chen LY, et al. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guerin treatment failure. J Urol 2013;190(5):1686-91
102. Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161(4): 1124-7
103. Orihuela E, Herr HW, Pinsky CM, Whitmore WF Jr. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60(3):326-33
104. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990;144(6):1328-30
105. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429-34
106. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4 Pt 1): 1242-7
107. Pagano F, Bassi P, Milani C, et al. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991;146(1):32-5
108. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 2000;55(2): 161-8
109. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36(2):140-8
110. Secanella-Fandos S, Noguera-Ortega E, Olivares F, et al. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guerin retains the antitumor ability of live bacillus Calmette-Guerin. J Urol 2014;191(5):1422-8
111. Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000; 68(12):6883-90
112. Hayashi A, Doi O, Azuma I, Toyoshima K. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Japan Acad Series B 1998;74(3):50-5
113. Udagawa M, Kudo-Saito C, Hasegawa G, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 2006;12(24): 7465-75
114. Yuk JM, Shin DM, Song KS, et al. Bacillus Calmette-Guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 2010;6(1): 46-60
115. Ikeda N, Honda I, Yano I, et al. Bacillus Calmette-Guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. J Urol 2005;173(5): 1507-12
116. Irie A, Uchida T, Yamashita H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence. Int J Urol 2003;10(4):183-9
117. Secanella-Fandos S, Luquin M, Julian E. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J Urol 2013;189(2):711-18
118. Holmgren I. Employment of B. C. G., especially in intravenous injection. Acta Medica Scandinavica 1936;90(S78):350-61
119. Old LJ, Clarke DA, Benacerraf B. Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959;184(Suppl 5):291-2
120. Weiss DW, Bonhag RS, Leslie P. Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts. J Exp Med 1966;124(6): 1039-65
121. Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 1971; 172(3980):271-3
122. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma 1. Surgery 1970;68(1): 158-63
123. Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 1976;60(3):419-30
124. Falk RE, MacGregor AB, Ambus U, et al. Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer. Dis Colon Rectum 1977;20(3): 215-22
125. Stewart JH, Levine EA. Role of bacillus Calmette-Guerin in the treatment of advanced melanoma. Expert Rev Anticancer Ther 2011;11(11):1671-6
126. Morales A, Wilson JL, Pater JL, Loeb M. Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial. J Urol 1982;127(2): 230-5
127. Dagnone AJ, Young ID, Morales A. Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy. Can J Urol 1999;6(2): 749-50
128. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20(2):283-95
129. Mavrichev AS, Grigorovich NA, Sukonko OG, Rovbut' II. The late results of the combined treatment of kidney cancer patients. Urol Nefrol (Mosk) 1990(5):13-16
130. Robinson MR, Rigby CC, Pugh RC, Dumonde DC. Prostate carcinoma: intratumor BCG immunotherapy. Natl Cancer Inst Monogr 1978(49):351-3
131. Robinson MR, Rigby CC, Pugh RC, Dumonde DC. Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol 1977;49(3):221-6
132. Guinan PD, John T, Baumgartner G, et al. Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol 1982; 5(1):65-8
133. Risk M, Corman JM. The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol 2009;11(1):16-27
134. Dietrich G, Viret JF, Hess J. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG 1. Int J Med Microbiol 2003;292(7-8):441-51
135. Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins 1. Microbes Infect 2005;7(5-6):947-54
136. Stover CK, de la Cruz VF, Fuerst TR, et al. New use of BCG for recombinant vaccines. Nature 1991;351(6326):456-60
137. Grode L, Kursar M, Fensterle J, et al. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 2002;168(4):1869-76
138. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9(5):533-9
139. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97(25):13853-8
140. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005; 115(9):2472-9
141. Kawahara M, Matsuo K, Honda M. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs. Clin Immunol 2006;119(1):67-78
142. Cayabyab MJ, Korioth-Schmitz B, Sun Y, et al. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 2009; 83(11):5505-13
143. Wang C, Fu R, Chen Z, et al. Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B. Clin Dev Immunol 2012;2012:563838
144. Sugawara I, Sun L, Mizuno S, Taniyama T. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 2009;89(1):62-7
145. Dey B, Jain R, Khera A, et al. Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs. Vaccine 2009; 28(1):63-70
146. Shi C, Chen L, Chen Z, et al. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 2010;28(32):5237-44
147. Wang J, Qie Y, Zhu B, et al. Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Med Microbiol Immunol 2009;198(1):5-11
148. Qie YQ, Wang JL, Liu W, et al. More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. Scand J Immunol 2009;69(4):342-50
149. Mohamud R, Azlan M, Yero D, et al. Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guerin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens. BMC Immunol 2013;14(Suppl 1): S5
150. Rizzi C, Bianco MV, Blanco FC, et al. Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One 2012;7(12):e51396
151. Shen H, Wang C, Yang E, et al. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol 2010;54(8):435-41
152. Xu Y, Liu W, Shen H, et al. Recombinant Mycobacterium bovis BCG expressing chimaeric protein of Ag85B and ESAT-6 enhances immunostimulatory activity of human macrophages. Microbes Infect 2010;12(8-9):683-9
153. Deng YH, He HY, Zhang BS. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6. J Microbiol Immunol Infect 2014;47(1):48-56
154. Nunes-Alves C, Booty MG, Carpenter SM, et al. In search of a new paradigm for protective immunity to TB 1. Nat Rev Microbiol 2014;12(4):289-99
155. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis 1. Infect Immun 2003;71(4): 1672-9
156. Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers 1. J Infect Dis 2008;198(10): 1491-501
157. Hess J, Miko D, Catic A, et al. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998;95(9):5299-304
158. Desel C, Dorhoi A, Bandermann S, et al. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011;204(10):1573-84
159. da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 2014;5:152
160. Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013;31(9):1340-8
161. Velmurugan K, Grode L, Chang R, et al. Nonclinical development of bcg replacement vaccine candidates. Vaccines (Basel) 2013; 1(2):120-38
162. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine 1. Science 2011; 334(6062):1488-90
163. Rowland R, McShane H. Tuberculosis vaccines in clinical trials 1. Expert Rev Vaccines 2011;10(5):645-58
164. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? 1. PLoS Pathog 2012;8(5):e1002607
165. Nascimento IP, Dias WO, Mazzantini RP, et al. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 2000;68(9): 4877-83
166. Nascimento IP, Dias WO, Quintilio W, et al. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect 2008;10(2):198-202
167. Nascimento IP, Dias WO, Quintilio W, et al. Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates. Vaccine 2009;27(52): 7346-51
168. Chege GK, Burgers WA, Stutz H, et al. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP primeboost HIV vaccine candidate in a nonhuman primate model. J Virol 2013; 87(9):5151-60
169. Wei SH, Yin W, An QX, et al. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol 2008;153(6):1021-9
170. Li WC, Zhang XK, Du L, et al. Eimeria maxima: efficacy of recombinant Mycobacterium bovis BCG expressing apical membrane antigen1 against homologous infection. Parasitol Res 2013;112(11): 3825-33
171. O'Donnell MA, Aldovini A, Duda RB, et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994;62(6):2508-14
172. Young S, O'Donnell M, Lockhart E, et al. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol 2002;80(3):209-15
173. Chung MA, Luo Y, O'Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003;63(6):1280-7
174. Biet F, Kremer L, Wolowczuk I, et al. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 2002;70(12):6549-57
175. Liu W, O'Donnell MA, Chen X, et al. Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 2009;58(10):1647-55
176. Arnold J, de Boer EC, O'Donnell MA, et al. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 2004;27(2):116-23
177. Chege GK, Thomas R, Shephard EG, et al. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 2009;27(35):4857-66
178. Chapman R, Shephard E, Stutz H, et al. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One 2012; 7(3):e32769
179. Hopkins R, Bridgeman A, Bourne C, et al. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 2011;41(12): 3542-52
180. Rahman S, Magalhaes I, Rahman J, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8(+) cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol Med 2012;18:647-58
181. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial 1. Lancet 2013;381(9871):1021-8
182. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis 1. Infect Immun 2009;77(8): 3364-73
183. Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques 1. PLoS One 2009;4(4):e5264
184. Scriba TJ, Tameris M, Mansoor N, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants 1. J Infect Dis 2011;203(12):1832-43
185. Scriba TJ, Tameris M, Mansoor N, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells 1. Eur J Immunol 2010;40(1):279-90
186. Upadhyay P. Tuberculosis vaccine trials 1. Lancet 2013;381(9885):2253-4
187. Dye C, Fine PE. A major event for new tuberculosis vaccines. Lancet 2013; 381(9871):972-4
188. Tchakoute CT, Hesseling AC, Kidzeru EB, et al. Delaying BCG Vaccination Until 8 Weeks of Age Results in Robust BCG-Specific T-Cell Responses in HIV-Exposed Infants 1. J Infect Dis 2015; 211(3):338-46
189. Ding GQ, Yu YL, Shen ZJ, et al. Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guerin vaccine on bladder cancer cells. J Zhejiang Univ Sci B 2012;13(5):335-41
190. Yuan S, Shi C, Ling R, et al. Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol 2010;136(9): 1359-67
191. Yuan S, Shi C, Lv Y, et al. A novel Bacillus Calmette-Guerin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm 2009;24(5):607-13
192. Evolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 2005;100(5):459-65
193. Mortatti RC, Maia LC, Fonseca LS. Absorption of Mycobacterium bovis BCG administered by the oral route. Vaccine 1987;5(2):109-14
194. Aldwell FE, Tucker IG, de Lisle GW, Buddle BM. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect Immun 2003; 71(1):101-8
195. Aldwell FE, Cross ML, Fitzpatrick CE, et al. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis 1. Vaccine 2006;24(12): 2071-8
196. Mazzantini RP, Miyaji EN, Dias WO, et al. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine 2004; 22(5-6):740-6
197. Miyaji EN, Mazzantini RP, Dias WO, et al. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun 2001;69(2):869-74
198. Kim YJ. Efficiency of recombinant bacille Calmette-Guerin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice. Yonsei Med J 2011;52(1):173-80
199. Sato H, Jing C, Isshiki M, et al. Immunogenicity and safety of the vaccinia virus LC16m8Delta vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol. Vaccine 2013; 31(35):3549-57
200. Kawahara M. Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. Clin Immunol 2008;129(3):492-8
201. Yasutomi Y, Koenig S, Haun SS, et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993; 150(7):3101-7
202. Uno-Furuta S, Matsuo K, Tamaki S, et al. Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine 2003; 21(23):3149-56
203. Palavecino CE, Cespedes PF, Gomez RS, et al. Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus. J Immunol 2014;192(1): 214-23
204. Teo WH, Nurul AA, Norazmi MN. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum. Trop Biomed 2012;29(2): 239-53
205. Nurul AA, Norazmi MN. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1 (19)) antigen of Plasmodium falciparum. Parasitol Res 2011;108(4):887-97
206. Yu Q, Huang X, Gong P, et al. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine 2013;31(51): 6065-71
207. Li WG, Wang H, Zhu YM. Change of splenocyte lymphokines in mice induced by recombinant BCG-Eg95 vaccine against Echinococcus granulosus. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2007;25(2):109-13
208. Varaldo PB, Leite LC, Dias WO, et al. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun 2004;72(6): 3336-43